Time Sensitivity: A Parameter Reflecting Tumor Metabolic Kinetics by Variable Dual-Time F-18 FDG PET Imaging

ObjectivesThe aim of this study was to define and investigate the time sensitivity of tumors by variable dual-time fluorodeoxyglucose positron emission tomography (FDG PET).MethodsVariable dual-time (t) protocol (P) FDG PET–computed tomography (CT) scans from 40 patients with pathologically proven head and neck tumors without brain metastasis were analyzed. The first protocol (P.I) consisted of 26 patients with early (E) and delayed (D) PET–CT obtained at 106 ± 15 and 135 ± 16 min after injection of 16.3 ± 1.9 mCi FDG. The second protocol (P.II) recruited 14 patients with E- and D-PET performed at 54 ± 13 and 151 ± 28 min after injection of 9.6 ± 1.7 mCi FDG. The maximum standardized uptake values (SUVs) were measured in the primary tumor (CA1) and the cerebellum (CBL). The time sensitivity (S) was defined as d{ln(SUV)}/d{ln(t)} and its value was obtained by linear regression of ln(D-SUV/E-SUV) vs ln(tD/tE). Patients with cerebellar variations greater than 30% in SUV between E- and D-PET was excluded from the analysis.ResultsTwo patients from P.I were excluded due to wide cerebellar SUV variations. D-SUV were significantly higher than E-SUV in CA1 for both P.I (18.9 ± 6.9 vs 14.8 ± 5.6, p < 0.0005) and P.II (11.5 ± 7.9 vs 9.7 ± 6.9, p = 0.013). The S values for CA1 in P.I and P.II were 0.67 and 0.17, respectively. The D-SUV were also higher than E-SUV in CBL for both P.I (12.5 ± 1.6 vs 11.6 ± 1.6, p < 0.0005) and P.II (7.6 ± 1.6 vs 7.0 ± 1.6, p = 0.008). The S values for CBL in P.I and P.II were 0.47 and 0.04, respectively, which were over 1.4-fold smaller than that of CA1, suggesting fundamental kinetic differences between CA1 and CBL.ConclusionsThe time sensitivity factor reflects another kinetic parameter of tumor metabolism besides SUV when using variable dual-time FDG PET. It offers another useful diagnostic tool in optimizing choices of dual-time protocols for oncologic PET–CT and in reducing SUV variations due to time interval differences with corrections using S.

[1]  Dafang Wu,et al.  Granulomatous disease: is it a nuisance or an asset during PET/computed tomography evaluation of lung cancers? , 2008, Nuclear medicine communications.

[2]  P. Marsden,et al.  A PET study of 18FDG uptake in soft tissue masses , 1999, European Journal of Nuclear Medicine.

[3]  E. Hoffman,et al.  Noninvasive determination of local cerebral metabolic rate of glucose in man. , 1980, The American journal of physiology.

[4]  A. Alavi,et al.  Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions. , 2009, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[5]  D. Yan,et al.  Correlating metabolic and anatomic responses of primary lung cancers to radiotherapy by combined F-18 FDG PET-CT imaging , 2007, Radiation oncology.

[6]  T. Yen,et al.  Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Sinha,et al.  Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy , 2003, Nuclear medicine communications.

[8]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[9]  R. Birdwell,et al.  Potential of Dual-Time-Point Imaging to Improve Breast Cancer Diagnosis with 18F-FDG PETKumar R, Loving VA, Chauhan A, et al (Univ of Pennsylvania, Philadelphia) J Nucl Med 46:1819–1824, 2005§ , 2007 .

[10]  N. Obuchowski,et al.  Comparison of double-phase 99mTc-sestamibi with 123I-99mTc-sestamibi subtraction SPECT in hyperparathyroidism. , 1997, AJR. American journal of roentgenology.

[11]  T. Saga,et al.  Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  J. Thie,et al.  Investigating the Existence of Quantum Metabolic Values in Non-Hodgkin’s Lymphoma by 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography , 2006, Molecular Imaging and Biology.

[13]  D. Yan,et al.  Clinical implications of defining the gross tumor volume with combination of CT and 18FDG-positron emission tomography in non-small-cell lung cancer. , 2007, International journal of radiation oncology, biology, physics.

[14]  L M Hamberg,et al.  The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  Addressing glucose sensitivity measured by F-18 FDG PET in lung cancers for radiation treatment planning and monitoring. , 2006, International journal of radiation oncology, biology, physics.

[16]  Y. Inoue,et al.  Thallium‐201‐chloride thyroid scintigraphy to evaluate benign and/or malignant nodules usefulness of the delayed scan , 1982, Cancer.

[17]  J. Thie,et al.  Glucose-normalized standardized uptake value from (18)F-FDG PET in classifying lymphomas. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  Abass Alavi,et al.  Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  Joseph A. Thie Optimizing Dual-Time and Serial Positron Emission Tomography and Single Photon Emission Computed Tomography Scans for Diagnoses and Therapy Monitoring , 2007, Molecular Imaging and Biology.

[20]  T. A. Smith,et al.  FDG uptake, tumour characteristics and response to therapy: A review , 1998, Nuclear medicine communications.

[21]  R. Hardoff,et al.  Uptake of gallium-67 citrate and [2-3H]deoxyglucose in the tumor model, following chemotherapy and radiotherapy. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.